Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer.
Seo YD, Jiang X, Sullivan KM, Jalikis FG, Smythe KS, Abbasi A, Vignali M, Park JO, Daniel SK, Pollack SM, Kim TS, Yeung R, Crispe IN, Pierce RH, Robins H, Pillarisetty VG. Seo YD, et al. Among authors: smythe ks. Clin Cancer Res. 2019 Jul 1;25(13):3934-3945. doi: 10.1158/1078-0432.CCR-19-0081. Epub 2019 Apr 2. Clin Cancer Res. 2019. PMID: 30940657 Free PMC article.
Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses.
Brempelis KJ, Cowan CM, Kreuser SA, Labadie KP, Prieskorn BM, Lieberman NAP, Ene CI, Moyes KW, Chinn H, DeGolier KR, Matsumoto LR, Daniel SK, Yokoyama JK, Davis AD, Hoglund VJ, Smythe KS, Balcaitis SD, Jensen MC, Ellenbogen RG, Campbell JS, Pierce RH, Holland EC, Pillarisetty VG, Crane CA. Brempelis KJ, et al. Among authors: smythe ks. J Immunother Cancer. 2020 Oct;8(2):e001356. doi: 10.1136/jitc-2020-001356. J Immunother Cancer. 2020. PMID: 33115946 Free PMC article.
Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy.
Wisdom AJ, Mowery YM, Hong CS, Himes JE, Nabet BY, Qin X, Zhang D, Chen L, Fradin H, Patel R, Bassil AM, Muise ES, King DA, Xu ES, Carpenter DJ, Kent CL, Smythe KS, Williams NT, Luo L, Ma Y, Alizadeh AA, Owzar K, Diehn M, Bradley T, Kirsch DG. Wisdom AJ, et al. Among authors: smythe ks. Nat Commun. 2020 Dec 17;11(1):6410. doi: 10.1038/s41467-020-19917-0. Nat Commun. 2020. PMID: 33335088 Free PMC article.
Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade.
Srivastava S, Furlan SN, Jaeger-Ruckstuhl CA, Sarvothama M, Berger C, Smythe KS, Garrison SM, Specht JM, Lee SM, Amezquita RA, Voillet V, Muhunthan V, Yechan-Gunja S, Pillai SPS, Rader C, Houghton AM, Pierce RH, Gottardo R, Maloney DG, Riddell SR. Srivastava S, et al. Among authors: smythe ks. Cancer Cell. 2021 Feb 8;39(2):193-208.e10. doi: 10.1016/j.ccell.2020.11.005. Epub 2020 Dec 24. Cancer Cell. 2021. PMID: 33357452 Free PMC article.
CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes.
Schroeder BA, LaFranzo NA, LaFleur BJ, Gittelman RM, Vignali M, Zhang S, Flanagan KC, Rytlewski J, Riolobos L, Schulte BC, Kim TS, Chen E, Smythe KS, Wagner MJ, Mantilla JG, Campbell JS, Pierce RH, Jones RL, Cranmer LD, Pollack SM. Schroeder BA, et al. Among authors: smythe ks. J Immunother Cancer. 2021 Aug;9(8):e002812. doi: 10.1136/jitc-2021-002812. J Immunother Cancer. 2021. PMID: 34465597 Free PMC article.
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma.
Phillips D, Matusiak M, Gutierrez BR, Bhate SS, Barlow GL, Jiang S, Demeter J, Smythe KS, Pierce RH, Fling SP, Ramchurren N, Cheever MA, Goltsev Y, West RB, Khodadoust MS, Kim YH, Schürch CM, Nolan GP. Phillips D, et al. Among authors: smythe ks. Nat Commun. 2021 Nov 18;12(1):6726. doi: 10.1038/s41467-021-26974-6. Nat Commun. 2021. PMID: 34795254 Free PMC article. Clinical Trial.
Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells.
Goff PH, Riolobos L, LaFleur BJ, Spraker MB, Seo YD, Smythe KS, Campbell JS, Pierce RH, Zhang Y, He Q, Kim EY, Schaub SK, Kane GM, Mantilla JG, Chen EY, Ricciotti R, Thompson MJ, Cranmer LD, Wagner MJ, Loggers ET, Jones RL, Murphy E, Blumenschein WM, McClanahan TK, Earls J, Flanagan KC, LaFranzo NA, Kim TS, Pollack SM. Goff PH, et al. Among authors: smythe ks. Clin Cancer Res. 2022 Apr 14;28(8):1701-1711. doi: 10.1158/1078-0432.CCR-21-4239. Clin Cancer Res. 2022. PMID: 35115306 Free PMC article.
Immunologic Gene Signature Analysis Correlates Myeloid Cells and M2 Macrophages with Time to Trabectedin Failure in Sarcoma Patients.
Schroeder BA, Zhang Y, Smythe KS, Desai P, Thomas A, Viveiros P, Alexiev BA, Obeidin F, Chen EY, Cranmer LD, Wagner MJ, Jones RL, Campbell JS, Pierce RH, He Q, Pollack SM. Schroeder BA, et al. Among authors: smythe ks. Cancers (Basel). 2022 Mar 2;14(5):1290. doi: 10.3390/cancers14051290. Cancers (Basel). 2022. PMID: 35267598 Free PMC article.
A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma.
Wagner MJ, Zhang Y, Cranmer LD, Loggers ET, Black G, McDonnell S, Maxwell S, Johnson R, Moore R, Hermida de Viveiros P, Aicher L, Smythe KS, He Q, Jones RL, Pollack SM. Wagner MJ, et al. Among authors: smythe ks. Clin Cancer Res. 2022 Jun 1;28(11):2306-2312. doi: 10.1158/1078-0432.CCR-22-0240. Clin Cancer Res. 2022. PMID: 35349638 Free PMC article. Clinical Trial.
25 results